非小细胞肺癌免疫治疗进展

Progress in Immunotherapy of Non-Small Cell Lung Cancer

在世界范围内,肺癌是癌症相关死亡的最常见原因。在肺癌的常见类型中,非小细胞肺癌(Non-Small Cell Lung Cancer, NSCLC)占到了所有肺癌类型的85%,手术是其早期病变的主要治疗手段,但是单纯手术治疗后局部复发及转移复发率极高。不能手术切除的非小细胞肺癌曾经一般使用化学治疗、放射治疗等方案,但是收获的效果有限。在过去的20年里,非小细胞肺癌(NSCLC)的分子靶向治疗和免疫治疗显著地改善了疗效,特别是免疫治疗在非小细胞肺癌的治疗中已经成为标准治疗方法之一。本文就目前关于非小细胞肺癌免疫治疗进展作一综述。

Lung cancer stands as the leading cause of cancer-related mortality all over the word. Non-Small Cell Lung Cancer (NSCLC), among the common lung cancer types, constitutes 85% of all cases. While surgery remains the primary treatment for early-stage lesions, the post-surgical rates of local re-currence and metastasis are notably high. Chemotherapy and radiotherapy are conventional ap-proaches for unresectable NSCLC;however, their efficacy is often limited. Over the past two decades, molecular targeted therapy and immunotherapy have markedly enhanced the outcomes for NSCLC. Notably, immunotherapy has emerged as a standard treatment modality for NSCLC. This paper re-views the advancements in immunotherapy for non-small cell lung cancer.